

AOFAS Research Grant Application Instructions

You are about to fill out the application form for the AOFAS RESEARCH GRANTS PROGRAM. Please have your answers to the application form ready before you begin.

1) Ensure that at least one of your principal investigators or co-investigators is an AOFAS member who is in good standing and in one of the following membership categories: Active Member, Candidate Member, or International Member.

2) Please have all answers ready before you log in and fill out the application form.

3) You will need to upload a [RESEARCH STRATEGY](#) document for your study. Name the file as “PI lastname_ResearchStrategy_First three words of study title” (example: “Smith_ResearchStrategy_Correlation Regression of”).

4) You will need to upload a [BIBLIOGRAPHY](#) document for your study. It should be an MS Word file, 6 pages or less. Name the file as “PI lastname_Biblio_First three words of study title”.

5) IRB Document to Upload:

5a) If your study requires it, you will be asked to upload a copy of your IRB approval letter.

5b) If your study has animal subjects, you will be required to upload an IACUC approval document.

5c) If your study requires NIH approval, you will be required to upload your NIH OLAW document.

6) You will need to upload a [BUDGET](#) document for your study. Fill out the template and save your document as “PI lastname_Budget_First three words of study title”. Grant awards may not be used for the salary of the Principal Investigator(s) or the Co-Investigator(s).

7) You will need to upload a [BIOGRAPHICAL SKETCH](#) of your each of your PIs and CIs. Please upload one document containing all the documents of your PIs and CIs. Please name it using “BIO_First three words of your study title”

8) You will need to upload the [ATTESTATION FORM](#), signed by all investigators (PIs and CIs). Name your document as “PI lastname_Attestation_First three words of study title”.

9) All investigators (PIs and CIs) need to upload a [DISCLOSURE FORM](#). Please upload only one document containing the disclosure forms of all the PIs and CIs in the study. Do not upload separate disclosure forms for each PI or CI.

Please make sure you have all documents uploaded before you click “SUBMIT” in your application form. If you have questions, please email research@aofas.org. Thank you.

Research Grant Application

Example Research Strategy

(version 2021Aug12)

Direction:

1) Address the following regarding your study:

SIGNIFICANCE

INNOVATION

APPROACH

TIMELINE

2) Must be 6 pages or less. Use the example document below.

Significance

Osteochondral defects (OCDs) of the talus refer to focal lesions of the talar articular cartilage and subchondral bone. They are common with acute ankle trauma, as 50% of sprains and 73% of fractures have been associated with talar OCDs.¹ While less frequent, idiopathic cases have also been reported². Current strategies for surgical management fall into two categories: restoration and replacement. The primary restorative technique is microfracture, in which penetration of the subchondral bone recruits marrow-derived stem cells to replace cartilage lesions with biomechanically inferior fibrocartilage. It is regarded as the standard treatment, although utilization has been questioned for large lesions (>150 mm²) and those with a considerable cystic component.³ Alternative techniques aim to replace defects with bone grafts or chondrocytes harvested and cultured *in vitro*, and include chondrocyte implantation, particulated juvenile cartilage allograft, and osteochondral grafts. Prior studies have evaluated the efficacy of current restoration strategies compared with microfracture³⁻¹³; however, in part due to the lack of large comparative studies, there are no widely accepted guidelines for treatment.

The primary focus of this study is to investigate midterm outcomes across the spectrum of arthroscopic techniques for treating OCDs of the talus. With a breadth of pre-, intra-, and postoperative data collection points and a cohort compiled from multiple high volume arthroscopists, this study aims to bring clarity to the decision-making algorithm for talar OCDs. In addition to comparative analyses of OCD procedures, we intend to investigate OCDs in the context of concomitant pathology. With operative data on ankle instability, anterior and posterior impingement, peroneal tendinopathy, fracture status, and Achilles tendinopathy, this study is equipped to analyze variations in outcomes with concomitant lesions.

The paucity of available outcomes data from prospective studies limits current recommendations for treatment strategies. Achievement of this study's aims will provide an adequately powered evidence base to guide clinical decision-making with talar OCDs.

Innovation

Limitations in statistical power are widespread in the orthopedic literature.¹⁴ These problems are especially relevant in the arthroscopic management of talar OCDs, as the number of arthroscopists capable of managing talar OCDs is limited by the field's recent emergence, and the extent of procedural variation with this pathology demands a large cohort for comparative analyses. A single institution may be limited in volume to evaluate the suite of available cartilage restoration techniques, particularly if performed at low frequencies. A multicenter prospective study may alleviate these concerns. Our collaboration across seven orthopedic foot and ankle specialty sites allows for robust analysis of the relationship between treatment method and clinical outcome.

While multicenter collaboration improves data volume, precautions must be taken to minimize the variation inherent with collection at multiple sites. While unable to control for all factors, standardizations required of this study include pre-operative management, intra-operative consistency, and post-operative rehabilitation protocols. The seven eligible sites perform an average of 23 OCD arthroscopies per year, and have agreed to adhere to a group-wide protocol for data collection. For primary OCDs without

concomitant pathology, patients must fail a conservative regimen of NSAIDs, physical therapy, and rest for 4-6 months before being considered for arthroscopic intervention. Intra-operative approaches and techniques at each site have been reviewed by the Principal Investigator for significant variation relative to the other co-investigators. Compliance monitoring across multiple sites takes place via the Surgical Outcomes System (SOS) software, verified by support staff for accuracy and presented at monthly meetings between study coinvestigators. Rehabilitation protocols for OCDs and other concomitant pathologies have been established.

Multicenter collaboration is facilitated through SOS, a cloud-based, secure repository with a module customized specifically for this study. Automated email and text messages have been incorporated to remind patients prior to follow-up time points. Given that automatic electronic reminders yield response rates deemed insufficient for the purposes of this study¹⁵, each site is required to designate support staff to make personal phone calls to non-compliant patients.

Approach

All study procedures are considered routine. Criteria for study inclusion are an arthroscopy performed specifically for an OCD or an OCD identified during arthroscopic treatment of other ankle pathologies, and completed pre-operative outcomes questionnaires. Exclusion criteria are evidence of osteoarthritis, the presence of rheumatologic diseases such as rheumatoid arthritis, SLE, or crystalline diseases, a previous history of ankle joint infection, joint malalignment secondary to previous trauma, or an inability to be contacted by phone or email. Each of the seven participating centers will collect and store data using the previously described SOS system. Data collection will take place preoperatively, intraoperatively and at two and five years postoperatively as described below:

Chart-Derived Preoperative Measures

	(13)	<i>Mechanism of injury</i>
	a.	<i>Slip/fall</i>
(1) <i>Height and weight</i>		b. <i>Motor vehicle accident</i>
(2) <i>Smoker (y/n)</i>		c. <i>Sports related</i>
(3) <i>Pre-operative use of narcotics (y/n)</i>		d. <i>Insidious</i>
(4) <i>Neuropathy (y/n)</i>		e. <i>Other</i>
(5) <i>Osteoporosis (y/n)</i>	(14)	<i>Other preoperative diagnoses</i>
(6) <i>Workman's compensation case (y/n)</i>		a. <i>Anxiety</i>
(7) <i>Marijuana use (y/n)</i>		b. <i>Depression</i>
(8) <i>Diabetic (y/n)</i>		c. <i>Fibromyalgia</i>
(9) <i>Use of vitamin D supplement (y/n)</i>		d. <i>Parkinson's</i>
(10) <i>Collagen disease (marfans/ehlersdanlos) (y/n)</i>		e. <i>Peripheral Arterial Disease</i>
(11) <i>Symptoms</i>		f. <i>Renal insufficiency</i>
a. <i>Pain with activity</i>		g. <i>Stroke</i>
b. <i>Catching/locking</i>		h. <i>Venous stasis</i>
c. <i>Shoe wear limitations</i>		i. <i>Rheumatoid arthritis</i>
d. <i>Pain at rest</i>		j. <i>Lumbar radiculopathy</i>
e. <i>Recurrent swelling</i>		
(12) <i>Duration of symptoms (months)</i>		

Patient Reported Measures (Preoperative, and at 2- and 5-years post-op)

- (1) Foot and Ankle Ability Measure (FAAM) Sports Subscale
- (2) Foot Function Index
- (3) VR-12 Health Index
- (4) Visual Analog Pain Scale (Foot)

Surgeon Reported Measures

- (1) Length/width/depth of defect post-debridement (mm)
- (2) Contained or noncontained
- (3) Hepple MRI
- (4) ICRS grade
- (5) Primary/revision surgery
- (6) Accessory portals used
- (7) Location of talar lesion
- (8) Procedure type
 - a. Chondroplasty
 - b. Microfracture
 - i. Microfracture awl or drilling/power pick
 - c. Autologous cartilage graft
 - i. ACI
 - ii. MACI
 - iii. Minced cartilage graft
 - iv. Other
 - d. Allograft cartilage graft
 - i. Minced juvenile
 - ii. Acellular scaffold
 - iii. Arthrex BioCartilage
 - iv. Cartiform
 - v. Other
 - e. Orthobiologic
 - i. Blood
 - ii. Plasma
 - iii. PRP (plasma-based system or buffy coat system)
 - iv. Bone marrow
 - v. Adipose
 - f. Osteochondral grafting
 - i. OATS autograft
 - ii. OATS allograft
 - iii. Bone graft + allogenic cartilage graft

- iv. Synthetic plug
- v. Bulk allograft
- vi. Average diameter and number of plugs used
- (9) Bone defect treatment alone (y/n)
 - a. Antegrade drilling (y/n)
 - b. Subchondroplasty (y/n)
 - c. Retrograde drilling (y/n)
- (10) Concomitant Pathologies
 - a. Lateral ankle instability
 - b. Medial ankle instability
 - c. Anterior impingement
 - d. Posterior impingement
 - e. Peroneal tendinopathy
 - f. Medial malleolar fracture
 - g. Lateral malleolar fracture
 - h. Posterior malleolar fracture
 - i. Achilles tendinopathy

Our joint-specific outcome measures are consistent with prior talar OCD studies: the Foot Function Index¹⁶ and the Foot and Ankle Ability Measure Sports Subscale¹⁷. The Veterans RAND 12-item Health Survey (VR-12) has been employed as a measure of overall physical and mental health in ankle pathology outcomes studies^{18,19}, and a visual analogue scale is included to measure changes in pain.

All staff entering data into the registry are members of the clinical care team, including physician assistants, nurses, medical assistants, and front office personnel. These professionals already have access to patient data and have completed CITI training in handling data from human research studies. The data entered into the SOS will be stripped of PHI and will be protected with password authentication for access to the data set. Information collected on the patient will remain confidential and professionals collecting data will maintain confidentiality of the patient throughout the process. Researchers from facilities that are not participating in the care of the patient may see the ID number, but will not be able to access personal information about the patient including their name. Chart-derived measures will be completed by clinical staff prior to operation date, and surgeon-reported measures within one day of performing the operation. Patient-reported outcomes are completed at two and five years after surgery.

Each patient is provided with an informational pamphlet upon consenting to participate in the study.

We have implemented standardized mechanisms of following up with patients beyond email and text message reminders from the data collection software. The clinical staff member responsible for compliance at each site will send the SOS reminder after a personal phone call to the patient. Attempts at contact will be made once a week starting at the time point and extending one month beyond. With no response, a personalized email and letter from the surgeon will be sent. Finally, a 10\$ Amazon gift card will be offered after 2 months of attempted contact and exhaustion of all other follow-up methods. We have recommended that each site keep a log of patient contact for accountability purposes.

No ubiquitous standard exists for post-operative rehabilitation with OCD procedures. A discussion between participating sites, along with consideration of the recommendations from the International Consensus Meeting on Cartilage Repair of the Ankle,²⁰ yielded the following guidelines for this study:

Microfracture

- *Time until range of motion: 1-2 weeks*
- *Length of immobilization, defined as total time in a boot, cast, splint, or brace: 4-8 weeks*
- *Time until weight bearing: 4-6 weeks. No high impact weight bearing for a minimum of 3 months*

Autologous chondrocyte implantation, particulated juvenile cartilage allograft, and osteochondral grafts

- *Time until range of motion: 1-2 weeks*
- *Length of immobilization: 6-12 weeks*
- *Time until weight bearing: 6 weeks. No high impact weight bearing for a minimum of 4-6 months*

Anterior impingement, posterior impingement and sinus tarsi. Synovectomy/debridement

- *Time until range of motion: 1-2 weeks*
- *Length of immobilization: 2-4 weeks*
- *Time until weight bearing: 1-2 weeks.*

Ankle instability repair or reconstruction

- *Time until range of motion: 1-2 weeks*
- *Length of immobilization: 6 weeks*
- *Time until weight bearing: 2 weeks*

In cases with concomitant pathology, the rehabilitation protocol that requires the longest protection period after the operation will be adopted.

One foreseeable problem is compliance with patient-reported outcomes. In our experience with registries involving multiple centers, completion rate of surgeon forms typically outpaces patient completion rates dramatically. An emphasis on patient compliance with this study is reflected in the requirement of clinical staff with the explicit responsibility and financial incentive for personal follow-up, and standardization across centers for mechanisms of data collection. A potential limitation is the rapid evolution of talar OCD procedures, specifically whether the landscape of operative strategies today will be relevant at final follow-up in five years. We are unable to account for future changes to standard practice; however, given the similarity of recommended techniques five years ago²¹ to those more recently²² and the incorporation of six procedural options in our collection strategy, we hope to buffer against future changes in the field.

An *a priori* fixed effects ANOVA power analysis for 6 groups with $\alpha=0.05$ and a small to medium effect size ($f=0.175$) yielded a total sample size of 426 required to reach a power of 0.8. Given the average of 23 arthroscopic procedures at each of the seven centers, we estimate three years of data collection (483 cases) to be sufficient. Interpretation of the data will occur with the assistance of a biostatistician, and we anticipate three avenues of analysis. First, a paired *t*-test will be performed to compare preoperative and postoperative patient-reported outcomes for each procedure type to assess improvement over time. Next, we will carry out multivariate linear regression to uncover associations between pre-operative or intra-operative factors and midterm subjective outcomes. Subsequently, we will stratify patients by procedure type while controlling for differences in baseline characteristics, and analyze changes in outcome scores to compare effectiveness by treatment type. The possibility of stratification by concomitant pathology to investigate the effect of multiple simultaneous lesions may be possible depending on the cohort size.

All centers have agreed to the benchmarks for success: >80% follow-up at all time points, and achieving the predicted cohort volume.

Project Timeline:

Date – Event

Date - Event

Date - Event

Example Bibliography

References

1. Barry MJ, Edgman-Levitan S. Shared decision making--pinnacle of patient-centered care. *N Engl J Med*. 2012;366(9):780–781. doi:10.1056/NEJMp1109283.
2. Bartunek J, Trullen J, Bonet E, Sauquet A. Sharing and expanding academic and practitioner knowledge in health care. *J Health Serv Res Policy*. 2003;8 Suppl 2:62–68. doi:10.1258/135581903322405199.
3. Berger K. Informed consent: information or knowledge? *Med Law*. 2003;22(4):743–750.
4. Cargo M, Mercer SL. The Value and Challenges of Participatory Research: Strengthening Its Practice. *Annu Rev Public Health*. 2008;29(1):325–350. doi:10.1146/annurev.publhealth.29.091307.083824.
5. Charles C, Gafni A, Whelan T. Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. *Soc Sci Med*. 1999;49(5):651–661. doi:10.1016/s0277-9536(99)00145-8.
6. Coulter A, Stilwell D, Kryworuchko J, Mullen PD, Ng CJ, van der Weijden T. A systematic development process for patient decision aids. *BMC Medical Informatics and Decision Making*. 2013;13(Suppl 2):S2. doi:10.1186/1472-6947-13-S2-S2.
7. Drake ER, Engler-Todd L, O'Connor AM, Surh LC, Hunter A. Development and Evaluation of a Decision Aid About Prenatal Testing for Women of Advanced Maternal Age. *J Genet Couns*. 1999;8(4):217–233. doi:10.1023/A:1022998415890.
8. Elwyn G. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. *BMJ*. 2006;333(7565):417–0. doi:10.1136/bmj.38926.629329.AE.
9. Fiset V, O'Connor AM, Evans W, Graham I, Degrasse C, Logan J. Development and evaluation of a decision aid for patients with stage IV non-small cell lung cancer. *Health Expect*. 2000;3(2):125–136. doi:10.1046/j.1369-6513.2000.00067.x.
10. Garvelink MM, Boland L, Klein K, et al. Decisional Conflict Scale Use over 20 Years: The Anniversary Review. *Med Decis Making*. 2019;39(4):301–314. doi:10.1200/JCO.2008.16.6215.
11. Golden-Biddle K, Reay T, Petz S, et al. Toward a communicative perspective of collaborating in research: the case of the researcher-decision-maker partnership. *J Health Serv Res Policy*. 2003;8 Suppl 2:20–25. doi:10.1258/135581903322405135.
12. Hertzog MA. Considerations in determining sample size for pilot studies. *Res Nurs Health*. 2008;31(2):180–191. doi:10.1016/S0895-4356(03)00141-0.
13. Hoffman AS, Bateman DR, Ganoe C, et al. Development and Field Testing of a Long-Term Care Decision Aid Website for Older Adults: Engaging Patients and Caregivers in User-Centered Design. Bowers BJ, ed. *The Gerontologist*. 2019;60(5):935–946. doi:10.1007/s11764-017-0649-5.
14. Hooiveld T, Molenaar JM, van der Heijde CM, Meijman FJ, Groen TP, Vonk P. End-user involvement in developing and field testing an online contraceptive decision aid. *SAGE Open Medicine*. 2018;6(4):205031211880946. doi:10.1016/j.pec.2010.10.011.
15. Jull J, Giles A, Graham ID. Community-based participatory research and integrated knowledge translation: advancing the co-creation of knowledge. December 2017:1–9. doi:10.1186/s13012-017-0696-3.

AOFAS Research Grant Application

Budget

May2022 version

Directions:

- 1) Complete the budget template.
- 2) Specify items and costs.
- 3) Grant awards/money cannot be used for salaries of PI or CI.
- 4) Equipment purchases over US\$5,000 are generally not permitted.
- 5) Any item taking a significant portion of the budget (equipment, personnel cost, etc.) requires explanation with rationale on the **Budget Justification** section.
- 6) Funds may not be used for travel.
- 7) Do **not** include names of people/institutions that would unblind the application to reviewers.
- 8) All costs should be entered in US\$.
- 9) When complete, enter **Total Project Budget** number in the designated field in the online application system.

1) SALARIES and WAGES		
List of personnel (No name, position only)	% of time in project	Cost
SALARIES TOTAL		

2) PERMANENT EQUIPMENT		
Equipment	Count	Cost
EQUIPMENT TOTAL		

3) CONSUMABLE SUPPLIES		
Supplies	Count	Cost
SUPPLIES TOTAL		

4) ANIMALS & ANIMAL CARE

Supplies	Count	Cost
ANIMAL CARE TOTAL		

5) OTHER EXPENSES

Supplies	Count	Cost
OTHER EXPENSES TOTAL		

TOTAL PROJECT BUDGET**

**Enter the TOTAL PROJECT BUDGET in the online application system.

BIOGRAPHICAL SKETCH for Principal Investigators & Co-Investigators

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME <i>Lastname, First Name</i>		POSITION TITLE <i>Associate Professor of Psychology</i>	
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	MM/YY	FIELD OF STUDY

A. Personal Statement

(Blue = Sample)

The goal of the proposed research is to investigate the interaction between drug abuse and normal aging processes. Specifically, we plan to measure changes in cognitive ability and mental and physical health across a five-year period in a group of older drug users and matched controls. I have the expertise, leadership and motivation necessary to successfully carry out the proposed work. I have a broad background in psychology, with specific training and expertise in key research areas for this application. As a postdoctoral fellow at Berkeley, I carried out ethnographic and survey research and secondary data analysis on psychological aspects of drug addiction. At the Division of Intramural Research at the National Institute on Drug Abuse (NIDA), I expanded my research to include neuropsychological changes associated with addiction. As PI or co-Investigator on several university- and NIH-funded grants, I laid the groundwork for the proposed research by developing effective measures of disability, depression, and other psychosocial factors relevant to the aging substance abuser, and by establishing strong ties with community providers that will make it possible to recruit and track participants over time. In addition, I successfully administered the projects (e.g. staffing, research protections, budget), collaborated with other researchers, and produced several peer-reviewed publications from each project. As a result of these previous experiences, I am aware of the importance of frequent communication among project members and of constructing a realistic research plan, timeline, and budget. The current application builds logically on my prior work, and I have chosen co-investigators (Drs. Gryczynski and Newlin) who provide additional expertise in cognition, gerontology and geriatrics. During 2005-2006 my career was disrupted due to family obligations. However, upon returning to the field I immediately resumed my research projects and collaborations and successfully competed for NIH support. In summary, I have a demonstrated record of accomplished and productive research projects in an area of high relevance for our aging population, and my expertise and experience have prepared me to lead the proposed project.

B. Positions and Honors

Positions and Employment

1998-2000 Fellow, Division of Intramural Research, National Institute of Drug Abuse, Bethesda, MD
2000-2002 Lecturer, Department of Psychology, Middlebury College, Middlebury, VT
2001- Consultant, Coastal Psychological Services, San Francisco, CA
2002-2005 Assistant Professor, Department of Psychology, Washington University, St. Louis, MO
2007- Associate Professor, Department of Psychology, Washington University, St. Louis, MO

Other Experience and Professional Memberships

1995- Member, American Psychological Association

1998- Member, Gerontological Society of America
1998- Member, American Geriatrics Society
2000- Associate Editor, *Psychology and Aging*
2003- Board of Advisors, Senior Services of Eastern Missouri
2003-05 NIH Peer Review Committee: *Psychobiology of Aging*, ad hoc reviewer
2007-11 NIH Risk, Adult Addictions Study Section, member

Honors

2003 Outstanding Young Faculty Award, Washington University, St. Louis, MO
2004 Excellence in Teaching, Washington University, St. Louis, MO
2009 Award for Best in Interdisciplinary Ethnography, International Ethnographic Society

C. Selected Peer-reviewed Publications (Selected from 42 peer-reviewed publications)

Most relevant to the current application

1. Merrylye, R.J. & Hunt, M.C. (2004). *Independent living, physical disability and substance abuse among the elderly*. *Psychology and Aging*, 23(4), 10-22.
2. Hunt, M.C., Jensen, J.L. & Crenshaw, W. (2007). *Substance abuse and mental health among community-dwelling elderly*. *International Journal of Geriatric Psychiatry*, 24(9), 1124-1135.
3. Hunt, M.C., Wiechelt, S.A. & Merrylye, R. (2008). *Predicting the substance-abuse treatment needs of an aging population*. *American Journal of Public Health*, 45(2), 236-245. PMID: PMC9162292
4. Hunt, M.C., Newlin, D.B. & Fishbein, D. (2009). *Brain imaging in methamphetamine abusers across the life-span*. *Gerontology*, 46(3), 122-145.
5. Hunt, M.C. & Sher, K.A. (2009). *Successful intervention models for older drug-abusers: Research across the life-span*. *American Psychologist*, in press. NIHMSID: NIHMS99135

Additional recent publications of importance to the field (in chronological order)

1. Gryczynski, J., Shaft, B.M., Merrylye, R., & Hunt, M.C. (2002). *Community based participatory research with late-life addicts*. *American Journal of Alcohol and Drug Abuse*, 15(3), 222-238.
2. Shaft, B.M., Hunt, M.C., Merrylye, R., & Venturi, R. (2003). *Policy implications of genetic transmission of alcohol and drug abuse in female nonusers*. *International Journal of Drug Policy*, 30(5), 46-58.
3. Hunt, M.C., Marks, A.E., Shaft, B.M., Merrylye, R., & Jensen, J.L. (2004). *Early-life family and community characteristics and late-life substance abuse*. *Journal of Applied Gerontology*, 28(2), 26-37.
4. Hunt, M.C., Merrylye, R. & Jensen, J.L. (2005). *The effect of social support networks on morbidity among elderly substance abusers*. *Journal of the American Geriatrics Society*, 57(4), 15-23.
5. Hunt, M.C., Pour, B., Marks, A.E., Merrylye, R. & Jensen, J.L. (2005). *Aging out of methadone treatment*. *American Journal of Alcohol and Drug Abuse*, 15(6), 134-149.
6. Hunt, M.C., Marks, A.E., Venturi, R., Crenshaw, W. & Ratonian, A. (2007). *Community-based intervention strategies for reducing alcohol and drug abuse in the elderly*. *Addiction*, 104(9), 1436-1606. PMID: PMC9000292
7. Merrylye, R. & Hunt, M.C. (2007). *Randomized clinical trial of cotinine in older nicotine addicts*. *Age and Ageing*, 38(2), 9-23. PMID: PMC9002364
8. Hunt, M.C., Jensen, J.L. & Merrylye, R. (2008). *The aging addict: ethnographic profiles of the elderly drug user*. NY, NY: W. W. Norton & Company.
9. Hunt, M.C. (2009). *Contrasting ethnicity with race in the older alcoholic*. *The Journals of Gerontology Series B: Psychological Sciences and Social Sciences*, in press. PMID: PMC Journal – In Process.
10. Hunt, M.C. (2009). *Intervening successfully with the older methadone patient*. *Journal of Applied Gerontology*, 13(4), 67-79.

D. Research Support

Ongoing Research Support

R01 DA942367-03 Hunt (PI) 09/01/08-08/31/13
Health trajectories and behavioral interventions among older substance abusers
The goal of this study is to compare the effects of two substance abuse interventions on health outcomes in an urban population of older opiate addicts.
Role: PI

R01 MH922731-05 Merryle (PI) 12/15/07-11/30/12
Physical disability, depression and substance abuse in the elderly
The goal of this study is to identify disability and depression trajectories and demographic factors associated with substance abuse in an independently-living elderly population.
Role: Co-Investigator

Faculty Resources Grant, Washington University 08/15/09-08/14/11
Opiate Addiction Database
The goal of this project is to create an integrated database of demographic, social and biomedical information for homeless opiate abusers in two urban Missouri locations, using a number of state and local data sources.

Completed Research Support

K02 AG442898 Hunt (PI) 02/01/02-01/31/05
Drug Abuse in the Elderly
Independent Scientist Award: to develop a drug addiction research program with a focus on substance abuse among the elderly.
Role: PI

R21 AA998075 Hunt (PI) 01/01/02-12/31/04
Community-based intervention for alcohol abuse
The goal of this project was to assess a community-based strategy for reducing alcohol abuse among older individuals.
Role: PI

AOFAS Research Grants Application

Attestation

(version 2020July9)

Direction: Everyone listed in the application form must read and approve this attestation, and provide an electronic signature. PIs, CIs, the Department Chair, Grant Administrator, Financial Officer need to sign this form. The group can use 1 document with all signatures in it.

I certify that statements in this application are true, complete, and accurate to the best of my knowledge. I accept the obligation to comply with the terms and conditions in the application instructions and in the AOFAS Research Grant Policies and Guidelines. If a grant is awarded as a result of this application, I am aware that any false, fictitious, or fraudulent statements or claims may subject my department or organization to administrative penalties. I agree to accept responsibility for the scientific conduct of the project and to provide the required INTERIM PROGRESS REPORT, FINAL REPORT, FAI MANUSCRIPT SUBMISSION, and ABSTRACT SUBMISSION if a grant is awarded as a result of this application.

Grant #: _____

Name	Signature	Date	Role
			Primary Investigator
			Co-Investigators
			Department Chair
			Grant Administrator
			Financial Officer
			Applicant (The person filling out the application form but not an PI, CI, chair, administrator, nor officer)
			Other (Please indicate role)

